Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Pfizer acquired Switzerland's Redvax for its innovative CMV vaccine
Jan. 5, 2015
 
Pfizer recently expanded its vaccine unit by acquiring Switzerland's Redvax to access to Redvax's novel human cytomegalovirus (CMV) vaccine candidate as well as the technology platform, just 1 month after it's buyout of Baxter's vaccines unit. CMV is a herpesvirus that infects 50% to 90% of the adult population and transmits from pregnant women to the fetuses.
 
China approved world's first Sabin IPV vaccine
Jan. 15, 2015
 
China's FDA has recently approved the world's first Sabin strain inactivated polio vaccine from the Chinese Academy of Medical Sciences .The vaccine will be incorporated into the EPI programs.
 
J&J gets 100M from IMI for Ebola vaccine development
Jan. 22, 2015
 
With the 100 million grant from the Innovative Medicines Initiative (IMI), J&J announced last Friday the formation of consortia with leading global research institutions and NGOs to accelerate the development of its Ebola vaccine, which might be the third in the world to get into clinical trials.
 
Dr.Wu attended BioPh&ICSE meeting in Beijing
Jan. 25, 2015
 
Biolink Bio-pharmaceutical Innovation and Tech-transfer meeting (BioPh&ICSE) was held in Beijing from Jan 22 to Jan 23 .
Dr.Wu was invited as a panelist to share his thoughts on biotech innovation and collaboration
 
GSK/NIH and Merck/NewLink's Ebola candidate will start Phase III trial in Liberia soon
Jan. 29, 2015
 
GSK and Merck/NewLink's experimental Ebola vaccine will be the first to undergo phase III clinical trials in Liberia, one of the main countries affected by Ebola. The Phase III trial, led by the NIH, is expected to involve up to 30,000 people, with one third receiving GSK's candidate, one third receiving a placebo, and the third group receiving Merck and NewLink's.
 
Serum may launch HPV vaccine in 2018 at one-third the price of Merck's Gardasil
Feb. 13, 2015
 
Merck sells Gardasil to the CDC at $113.54 per dose, and to UNICEF at $4.50 per dose this year. But, Indian Serum Institute, claiming to make the vaccines extremely affordable to even the poorest of the poor countries, may launch its tetravalent HPV vaccine in 2018 at about one-third the price of Merck's Gardasil. Serum will run clinical trials in India and Africa this year.
 
Novartis' Bexsero got FDA approval
Feb. 18, 2015
 
Novartis's meningitis B shot Bexsero recently got FDA approval, facing head to head competition from Pfizer's Trumenba which was approved by FDA in last October. But Bexsero's two-dose regimen and a flexible dosing schedule is surly an advantage over Trumenba's three dose regimen.
 
US CDC recommends Pfizer and Novartis's MenB vaccine
Feb. 26, 2015
 
Merck sells Gardasil to the CDC at $113.54 per dose, and to UNICEF at $4.50 per dose this year. But, Indian Serum Institute, claiming to make the vaccines extremely affordable to even the poorest of the poor countries, may launch its tetravalent HPV vaccine in 2018 at about one-third the price of Merck's Gardasil. Serum will run clinical trials in India and Africa this year.
 
EMA approved new Prevenar indication in Europe
Mar. 5, 2015
 
The European Medicines Agency (EMA) recently approved the expansion of pfizer's Prevenar in adults for prevention of pneumonia caused by the 13 pneumococcal serotype, based on the CAPiTA trial which showed that Prevenar cut first episodes of community-acquired pneumonia by 46% and first episodes of noninvasive CAP by 45%.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next